For at minimere den mulige risiko for posturale virkninger bør patienten - som ved andre antihypertensiver, inklusive alfa- blokerende midler - overvåges ved indledningen af behandlingen..
As for other antihypertensives, including alpha-blocking agents, the patient should be monitored on initiation of therapy to minimise the potential risk for postural effects.